Glp-1 and intestinal diseases

32Citations
Citations of this article
62Readers
Mendeley users who have this article in their library.

Abstract

Accumulating evidence implicates glucagon-like peptide-1 (GLP-1) to have, beyond glucose maintenance, a beneficial role in the gastrointestinal tract. Here, we review emerging data investigating GLP-1 as a novel treatment for intestinal diseases, including inflammatory bowel dis-eases, short-bowel syndrome, intestinal toxicities and coeliac disease. Possible beneficial mechanisms for these diseases include GLP-1′ s influence on gastric emptying, its anti-inflammatory properties and its intestinotrophic effect. The current knowledge basis derives from the available GLP-1 agonist treatments in experimental animals and small clinical trials. However, new novel strategies including dual GLP-1/GLP-2 agonists are also in development for the treatment of intestinal diseases.

Cite

CITATION STYLE

APA

Hunt, J. E., Holst, J. J., Jeppesen, P. B., & Kissow, H. (2021, April 1). Glp-1 and intestinal diseases. Biomedicines. MDPI AG. https://doi.org/10.3390/biomedicines9040383

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free